Form 4: Spero Therapeutics Director Milind Deshpande Acquires 20,000 Shares of Common Stock

Director Milind Deshpande acquired 20,000 shares of Spero Therapeutics common stock on May 29, 2024, in the form of restricted stock units.

Summary

• On May 29, 2024, Milind Deshpande, a director of Spero Therapeutics, acquired 20,000 shares of common stock.
• The acquisition was in the form of restricted stock units (RSUs).
• Each RSU represents the right to receive one share of common stock upon vesting.
• The RSUs vest on May 29, 2025, contingent upon Deshpande's continued service with the company.
• Following the transaction, Deshpande directly owns 71,454 shares of Spero Therapeutics common stock.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard insider transaction. The director's acquisition of shares could be interpreted as a positive sign, but it's not a strong indicator.

Positives

• The acquisition of shares by a director could be seen as a positive signal, indicating confidence in the company's future prospects.

Future Outlook

The vesting of the RSUs is contingent upon the Reporting Person's continued service through the applicable vesting date.

Industry Context

Form 4 filings are standard disclosures required by the SEC when insiders (directors, officers, and 10% owners) of a publicly traded company buy or sell the company's securities. These filings provide transparency to the market regarding insider transactions.

Stakeholder Impact

• The transaction could have a minor positive impact on shareholder sentiment, as it signals confidence from a company director.

Key Dates